Biotech Essentials

Startups

Biotech Startups Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 29.09.2021.

Biotechnology
Initial public offering
Therapy
Organism
New York Stock Exchange
Corporation

Startups

@ForbesTech shared
On Sep 24, 2021
RT @DavidJeans2: Startup CEOs often make profitability claims to journalists when their companies are private. But we found that 1 in 4 of the largest companies to IPO since Jan 2019 -- UiPath, Lyft, Palantir, Oscar Health, others -- told the SEC a different story. https://t.co/8mI2OEnSYA
Open
‘Enthusiastic Entrepreneurs’: Pre-IPO Statements On Profitability Prove To Be Larger Than Real Life

‘Enthusiastic Entrepreneurs’: Pre-IPO Statements On Profitability Prove To Be Larger Than Real Life

More than one in four of the 50 largest venture-backed companies to go public since 2019 made assertions about their profitability that don’t appear to line up with their later IPO-related ...

@FlagshipPioneer shared
On Sep 27, 2021
Congratulations to Flagship-founded @cellaritybio, @RepertoireIM, @ring_tx, @sendabioscience and @ValoHealth & to all @FierceBiotech 2021 #Fierce15 winners! https://t.co/gHd63uleiz
Open
Fierce Biotech's 2021 Fierce 15

Fierce Biotech's 2021 Fierce 15

COVID-19 was inevitably the focus of Fierce 15 last year. This year, it’s pretty much more of the same as we see how the sector has and continues to navigate the pandemic while raising ...

@ForbesTech shared
On Sep 22, 2021
RT @Forbes: Toast’s stock pops in Boston’s biggest-ever IPO, minting cofounders as billionaires https://t.co/w0DF7Bg2zJ https://t.co/tH8K2aFQOl
Open
Toast’s Stock Pops In Boston’s Biggest Ever IPO, Minting Cofounders As Billionaires

Toast’s Stock Pops In Boston’s Biggest Ever IPO, Minting Cofounders As Billionaires

The stock offering comes 16 months after Toast laid off half its employees.

@WSJVC shared
On Sep 23, 2021
To bring in top candidates, biotechs are trying to draw them on the strength of their firms' science and the company culture https://t.co/KxJPwKinuj
Open
Biotech Is on a Hiring Binge, But Lags Behind on Diversity

Biotech Is on a Hiring Binge, But Lags Behind on Diversity

It’s been a roaring year for the sector. But a survey finds women and people of color are still underrepresented at the top.

@Forbes shared
On Sep 27, 2021
Meet private equity’s quiet corporate turnaround artist: https://t.co/iKMNv25Ptc https://t.co/UOX7Z62tpH
Open
Meet Private Equity’s Quiet Corporate Turnaround Artist

Meet Private Equity’s Quiet Corporate Turnaround Artist

Advent International’s David Mussafer cuts a low profile on Wall Street, but his firm’s ability to reshape large companies has turned the firm from an also-ran into a fast-growing giant ...

@ForbesTech shared
On Sep 27, 2021
What Drives Newly Minted CRISPR Unicorn Mammoth Biosciences https://t.co/yzgP2IeJCM https://t.co/uvwJ5ou1cG
Open
What Drives Newly Minted CRISPR Unicorn Mammoth Biosciences

What Drives Newly Minted CRISPR Unicorn Mammoth Biosciences

Mammoth Biosciences has raised $195 million to build next-generation CRISPR products in therapeutics and diagnostics that can cure and detect diseases. Mammoth has now reached unicorn ...

@BusinessInsider shared
On Sep 27, 2021
The 3 most powerful psychedelics VCs dish on what they look for — and avoid — when investing in new companies https://t.co/4TdUmFqLWS
Open
The 3 most powerful psychedelics VCs dish on what they look for — and avoid — when investing in new companies

The 3 most powerful psychedelics VCs dish on what they look for — and avoid — when investing in new companies

Insider asked Noetic Fund, Palo Santo, and Neo Kuma about their strategies when deciding whether to invest in a company.

@FierceBiotech shared
On Sep 27, 2021
Ring: Viruses have been top of mind for billions of people, but one family of viruses could hold the key to a new set of gene therapies that try to do away with tolerability issues, tissue-specific tropism, lack of potency and re-dosing limitations. https://t.co/4h8vogPQFc
Open
Ring Therapeutics

Ring Therapeutics

Ring Therapeutics is exploring a variety of potential areas to pursue, including vaccines, ophthalmology and cardiology. All of them have potential for the company's anellovirus gene ...